Cartesian Therapeutics
RNAC
43 hedge funds and large institutions have $140M invested in Cartesian Therapeutics in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
48% more funds holding
Funds holding: 29 → 43 (+14)
32% more capital invested
Capital invested by funds: $106M → $140M (+$34.2M)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
1.5% more ownership
Funds ownership: 0% → 1.5% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$16.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.84M |
| 3 |
Millennium Management
New York
|
+$2.38M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$1.87M |
| 5 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$16.1M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.02M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$970K |
| 5 |
JP Morgan Chase
New York
|
-$930K |
RNAC Hedge Fund Activity: Q4 2016 in Review
43 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2016, worth a combined $140M — up 32% from $106M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RNAC positions and 4 closed out — a net gain of 14 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $16.6M. The largest seller was Flagship Pioneering, cutting an estimated $16.1M.
- 43 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2016, up from 29 in Q3 2016.
- Funds reported $140M of Cartesian Therapeutics stock for Q4 2016, up 32% quarter-over-quarter.
- 18 funds opened new Cartesian Therapeutics positions in Q4 2016 and 4 closed out, a net change of +14 holders.
- The largest Cartesian Therapeutics buyer in Q4 2016 was Deerfield Management, an estimated $16.6M added.
- The largest Cartesian Therapeutics seller in Q4 2016 was Flagship Pioneering, an estimated $16.1M sold.
Based on aggregated 13F filings for Q4 2016.